Skip to main content

Kaer NewsHealth

Lilly's retatrutide beats Ozempic, cutting weight 20.9% vs 9.4%

Eli Lilly's retatrutide lowered blood sugar by 2.2% and cut weight 20.9% versus Ozempic's 1.8% and 9.4% at 80 weeks in a late-stage diabetes trial reported on 28 October 2026.

3 min read
Lilly's retatrutide beats Ozempic, cutting weight 20.9% vs 9.4%Photo: STAT

Key points

Lilly's retatrutide outperformed Ozempic on weight loss and blood sugar control in an 80-week late-stage diabetes trial.

Eli Lilly said on Wednesday its experimental drug retatrutide outperformed Novo Nordisk's Ozempic on blood sugar control and delivered more than double the weight loss in a diabetes study. Both retatrutide doses lowered A1C, a measure of blood sugar over time, by an average of 2.2% compared with Ozempic's 1.8% at 80 weeks in the late-stage trial.

The results strengthen the competitive profile of retatrutide, which is widely expected to fuel Lilly's next wave of growth following the success of its Zepbound and Mounjaro. In previous studies, the drug has already shown a bariatric-surgery level of weight loss in patients with obesity, likely positioning it to be the most powerful drug in the booming market.

What the trial compared

The head-to-head trial compared 9 mg and 12 mg doses of retatrutide with a 2 mg dose of Novo's diabetes drug Ozempic. Lilly said the trial used the 2 mg dose as a comparator since it is the highest approved dose available. Those taking the higher dose of retatrutide lost 20.9% of their weight compared with 9.4% on Ozempic.

Retatrutide also delivered greater improvements than Ozempic across certain cardiovascular risk factors. The weight-loss gap — 20.9% versus 9.4% — is more than double, and the blood-sugar gap is 2.2% versus 1.8%, both measured at 80 weeks in the late-stage trial. The comparison used the highest approved Ozempic dose as the benchmark.

Commonly nicknamed triple-G, the once-weekly retatrutide activates GLP-1, GIP and glucagon hormone receptors. Triple-G drugs are expected to deliver greater weight loss than earlier generations by combining appetite suppression, blood sugar control and increased calorie burning. That three-receptor action explains why the drug lowered blood sugar and cut weight more than Ozempic alone.

How the triple-G mechanism works

Citi analyst Geoffrey Meacham said the data reaffirms retatrutide's differentiated efficacy across weight and glycemic control, strengthening its position as a key long-term cardiometabolic growth driver. The trial's design — matching two retatrutide doses against the top approved Ozempic dose — gives a direct read on how the drugs compare at their strongest settings.

Ozempic should not be judged solely on weight loss, said Ambre James-Brown, head of Novo's global media, noting that the highest doses of the diabetes drug have also shown benefits for heart, kidney and liver health. Novo's position is that Ozempic's value rests on organ benefits as well as the scale of weight reduction.

Lilly plans to seek approval for retatrutide in the U.S. next year and will present detailed results from the study at a future medical meeting. In another key late-stage study, Lilly is testing retatrutide against tirzepatide, the active ingredient in Zepbound, among adults with obesity with or without type 2 diabetes.

Frequently asked questions

How did retatrutide compare to Ozempic in the trial?

At 80 weeks, both retatrutide doses lowered A1C by 2.2% versus Ozempic's 1.8%, and the higher dose cut weight 20.9% versus 9.4% on Ozempic.

What doses were compared in the study?

The trial compared 9 mg and 12 mg retatrutide against 2 mg Ozempic, the highest approved Ozempic dose, which Lilly used as the comparator.

When will Lilly seek approval for retatrutide?

Lilly plans to seek U.S. approval for retatrutide next year and will present detailed study results at a future medical meeting.

More from this edition